Summary：Helus Pharma Closes US$50 Million Funding Deal, Fuels Breakthrough Innovation AheadNEW YORK and TORO

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Helus Pharma Closes US$50 Million Funding Deal, Fuels Breakthrough Innovation Ahead

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the successful closure of a US$50 million funding deal. This significant investment is poised to accelerate the company's pipeline of innovative treatments for mental health disorders, further solidifying its position as a leader in the pharmaceutical industry.

The funding, which was oversubscribed, saw participation from a mix of existing and new investors, underscoring the confidence in Helus Pharma's vision and its groundbreaking research in the field of mental health. The proceeds from this deal will be utilized to advance the company's flagship NSA program through late-stage clinical trials, with the ultimate goal of bringing these novel therapies to market. Helus Pharma's NSA program represents a promising new approach to treating a range of mental health conditions, including depression and anxiety disorders, by targeting specific serotonin receptor subtypes.

The mental health treatment landscape is ripe for innovation, with current therapies often falling short in terms of efficacy and tolerability. Helus Pharma's commitment to developing NSAs addresses this unmet need, offering the potential for more effective and better-tolerated treatments. Industry analysts view this development as a significant step forward, not only for Helus Pharma but for the mental health treatment sector as a whole. The successful funding round is a testament to the growing investor interest in innovative mental health solutions.

Looking ahead, Helus Pharma is well-positioned to make meaningful strides in the mental health treatment arena. With the funds raised, the company plans to expedite its clinical trials, potentially leading to FDA approval and commercialization of its lead NSA compound within the next three years. This timeline is ambitious but achievable, given the company's experienced management team and its strong research foundation.

In conclusion, Helus Pharma's successful US$50 million funding round is a landmark event that underscores the company's innovative approach to mental health treatment. As the company moves forward with its clinical-stage programs, it is poised to make a significant impact on the lives of millions of individuals worldwide who suffer from mental health disorders. With its novel serotonergic agonists, Helus Pharma is at the forefront of a new era in mental health care, one that promises more effective, targeted therapies.